Ratings MedinCell LIQUIDNET SYSTEMS

Equities

FR0004065605

End-of-day quote LIQUIDNET SYSTEMS Other stock markets			5-day change	1st Jan Change
- ^EUR	-.--%		-.--%	-.--%

Jun. 10	Transcript : MedinCell S.A., 2024 Earnings Call, Jun 10, 2024
Jun. 10	Medincell: a 'new era' after a 'pivotal' 2023	CF

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Over the past four months, analysts' average price target has been revised upwards significantly.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
MEDINCELL	-.--%	433M	-
ELI LILLY AND COMPANY	+50.70%	791B	C+
NOVO NORDISK A/S	+41.96%	630B	B
JOHNSON & JOHNSON	-7.15%	350B	C+
MERCK & CO., INC.	+18.77%	328B	B-
ABBVIE INC.	+8.79%	298B	C+
ASTRAZENECA PLC	+18.02%	246B	B+
ROCHE HOLDING AG	+1.27%	225B	A+
NOVARTIS AG	+11.95%	218B	B-
AMGEN INC.	+3.68%	160B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes